Physician profile
Vanessa E Harvey
NPI 1588283311
$4,244.45
in general payments reported to CMS, 2019-2025
25 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $901 · 2022: $1,666 · 2023: $440 · 2024: $1,003 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,511.40 | 2021-2025 | |
| Alkermes, INC. | $434.00 | 2021-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $426.03 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $312.34 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Jazz Pharmaceuticals INC. | $243.49 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $232.44 | 2021-2024 | Qelbree |
| Janssen Pharmaceuticals, INC | $190.17 | 2021-2024 | Invega Sustenna |
| Lundbeck LLC | $135.33 | 2023-2024 | Rexulti |
| Corium, LLC | $117.33 | 2022 | |
| Ironshore Pharmaceuticals INC. | $93.08 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $72.95 | 2021-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $68.38 | 2021-2022 | |
| Tris Pharma INC | $65.33 | 2024 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $63.41 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $57.26 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $35.54 | 2024 | |
| Noven Therapeutics, LLC | $35.37 | 2024-2025 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $34.98 | 2022-2023 | Auvelity |
| Merck Sharp & Dohme LLC | $24.13 | 2021-2022 | |
| Neos Therapeutics, LP | $19.45 | 2024 | Cotempla Xr-Odt |
| Bausch Health US, LLC | $17.70 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.43 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.49 | 2024 | Quviviq |
| Harmony Biosciences LLC | $13.10 | 2022 | |
| Adlon Therapeutics L.P. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.